Familial Hypertriglyceridemia: Genetics, Phenotypes, and Management
Familial hypertriglyceridemia refers to inherited disorders of triglyceride metabolism causing elevated plasma triglycerides. It encompasses several distinct genetic entities with varying inheritance, severity, and clinical implications.
Major Genetic Forms
1. Familial Combined Hyperlipidemia (FCHL)
- Inheritance: Complex/oligogenic (not single gene); autosomal dominant pattern in families.
- Phenotype: Elevated TG, elevated LDL-C, or both; variable expression within families. Low HDL common.
- Genetics: Multiple loci (USF1, APOA5, LPL, GCKR, APOE); polygenic score contributes.
- Prevalence: ~1-2% population; most common genetic dyslipidemia.
- Clinical: Premature ASCVD; often presents adulthood; exacerbated by obesity, insulin resistance, alcohol.
2. Familial Hypertriglyceridemia (FHTG) – "Type IV Hyperlipoproteinemia"
- Inheritance: Autosomal dominant (incomplete penetrance).
- Phenotype: Isolated VLDL elevation (TG 200-500 mg/dL); normal LDL-C, low-normal HDL.
- Genetics: Heterozygous variants in LPL, APOA5, APOC2, GPIHBP1, LMF1—reduce LPL activity. Polygenic background common.
- Precipitants: Alcohol, estrogen, uncontrolled diabetes, obesity, corticosteroids, retinoids.
3. Monogenic Severe Hypertriglyceridemia (Chylomicronemia Syndrome)
Autosomal recessive; TG >1,000 mg/dL (often >2,000); pancreatitis risk high. Presents childhood/young adulthood.
- LPL Deficiency: LPL loss-of-function (most common).
- ApoC-II Deficiency: APOC2 LOF—LPL cofactor absent.
- GPIHBP1 Deficiency: GPIHBP1 LOF—LPL not transported to capillary endothelium.
- LMF1 Deficiency: LMF1 LOF—LPL maturation defect.
- ApoA5 Deficiency: APOA5 LOF—severe hypertriglyceridemia, early pancreatitis.
4. Familial Dysbetalipoproteinemia (Type III)
- Genetics: APOE ε2/ε2 homozygosity (necessary but not sufficient) + second hit (obesity, diabetes, hypothyroidism, estrogen, renal disease).
- Phenotype: Elevated IDL (β-VLDL) → ↑ TG and ↑ Cholesterol (roughly equal). Palmar xanthomas, tuberoeruptive xanthomas. Premature ASCVD, peripheral artery disease.
Diagnostic Approach
- Fasting lipid panel (TG, TC, HDL-C, calculated LDL-C, non-HDL-C)
- Rule out secondary causes (uncontrolled diabetes, hypothyroidism, nephrotic syndrome, medications, alcohol)
- Family history + cascade screening
- Genetic testing: Panel for LPL, APOC2, APOA5, GPIHBP1, LMF1, APOE (commercial panels available). Confirms diagnosis, guides family screening, informs reproductive counseling.
- LPL activity (post-heparin)—specialized labs only.
Management
Lifestyle (Critical for All Forms)
- Very low-fat diet (<20% calories, <10% saturated)—especially for monogenic forms
- Strict alcohol avoidance
- Simple sugar/fructose restriction
- Weight optimization
- Glycemic control
- Omega-3 fatty acids (prescription EPA/DHA or icosapent ethyl)
Pharmacotherapy
| Disorder | First-Line | Add-On/Severe |
|---|---|---|
| FCHL | Statin (ASCVD risk-driven) | Fenofibrate, icosapent ethyl, ezetimibe |
| FHTG (moderate) | Fenofibrate, icosapent ethyl | Statin if LDL-C elevated |
| Monogenic (severe) | Very low-fat diet + fibrate + icosapent ethyl | Volanesorsen (ApoC-III ASO—FCS), evinacumab (ANGPTL3 Ab), plasmapheresis (acute pancreatitis) |
| Type III | Statin ± fibrate | Treat underlying precipitant |
Special Considerations
- Pregnancy: Physiologic TG rise (2-4×); discontinue fibrates, statins. Monitor; severe hypertriglyceridemia → pancreatitis risk. Omega-3 safe.
- Pediatric: Early dietary counseling; genetic confirmation; specialist follow-up.
- Cascade Screening: Identify at-risk relatives; early intervention prevents pancreatitis/ASCVD.
Prognosis
With modern therapy (especially icosapent ethyl, volanesorsen for familial chylomicronemia syndrome), pancreatitis risk dramatically reduced. ASCVD risk managed with statins. Lifelong adherence to diet and medication essential. Genetic counseling recommended.
Cardiovascular Disease - Related Articles
- Angina Treatment: Stents vs. Medication - What's Right for You?
- Rheumatic Heart Disease: Understanding Pathophysiology & Symptoms
- Understanding Circulatory System Diseases: Causes, Symptoms & Treatments
- Atria vs. Ventricles: Understanding Heart Chamber Differences
- Cardio for Body Recomposition: Realistic Timeline for Visible Changes
- Cardiovascular Disease Risk: Nonsmokers vs. Smokers – Key Statistics
- Diploma in Cardiology (DIP Card) - NBE India: Eligibility, Curriculum, and Career
